Later this month, page-39

Pierre, I tend to think after 11 yrs of trials trials starting with Euro, 78 patients over 90 days, Reach2HD, 106 people over 6 months then IMAGINE with about 40 patients out to as long as 2 years that it would be a waste of dogs and monkeys. If the HSG gets behind the recruitment I imagine a P3 could be started in the EU in reasonable time.
Omeros did the monkey tests and as far as I know they have still not got the dose in question into trials.
"Clinical trials in our Huntington’s program are currently subject to dosing limitations. The dosing limitations may potentially be removed pending generation, submission and FDA review of additional information. We are conducting nonclinical studies to generate additional data for further discussion with the FDA regarding the dosing limitations and are currently preparing for a re-designed Phase 2 clinical trial in patients with Huntington’s disease."
http://www.omeros.com/pipeline/pde10.htm